Jean Luc Houeto

ORCID: 0000-0002-6029-8289
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Neurological disorders and treatments
  • Parkinson's Disease Mechanisms and Treatments
  • Botulinum Toxin and Related Neurological Disorders
  • Transcranial Magnetic Stimulation Studies
  • Obsessive-Compulsive Spectrum Disorders
  • Advanced Neuroimaging Techniques and Applications
  • Genetic Neurodegenerative Diseases
  • Restless Legs Syndrome Research
  • Autism Spectrum Disorder Research
  • Cellular transport and secretion
  • Neurobiology of Language and Bilingualism
  • Aging and Gerontology Research
  • Genomics and Rare Diseases
  • Estrogen and related hormone effects
  • Psychological Well-being and Life Satisfaction
  • Sleep and Wakefulness Research
  • Nuclear Receptors and Signaling
  • Health, Medicine and Society
  • Orthopedic Infections and Treatments
  • Nicotinic Acetylcholine Receptors Study
  • Spatial Neglect and Hemispheric Dysfunction
  • Pain Mechanisms and Treatments
  • Radiopharmaceutical Chemistry and Applications
  • Ginkgo biloba and Cashew Applications
  • Pain Management and Placebo Effect

Inserm
2000-2025

Université de Limoges
2024-2025

Institut d’Epidémiologie Neurologique et de Neurologie Tropicale
2024-2025

French Clinical Research Infrastructure Network
2016-2025

Université de Poitiers
2011-2024

Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement
2024

Institut de Recherche pour le Développement
2024

Institut d’Epidémiologie et de Neurologie Tropicale
2024

Hôpital Universitaire Dupuytren
2022-2024

Centre Hospitalier Universitaire de Poitiers
2010-2022

<b><i>Objective:</i></b> To investigate the potential causes of excessive daytime sleepiness in patients with PD—poor sleep quality, abnormal sleep–wakefulness control, and treatment dopaminergic agents. <b><i>Methods:</i></b> The authors performed night-time polysomnography multiple latency tests 54 consecutive levodopa-treated PD referred for sleepiness, 27 whom were also receiving agonists. <b><i>Results:</i></b> Sleep was 6.3 ± 0.6 minutes (normal &gt;8 minutes), Epworth Sleepiness score...

10.1212/wnl.58.7.1019 article EN Neurology 2002-04-09

<b>Objective:</b> to analyse 24 parkinsonian patients successfully treated by bilateral STN stimulation for the presence of behavioural disorders. <b>Method:</b> were evaluated retrospectively adjustment disorders (social scale, SAS), psychiatric (comparison results interview and mini international neuropsychiatric inventory) personality changes (IOWA scale changes). <b>Results:</b> motor disability was improved 69.5% levodopa equivalent daily dosage reduced 60.5%. Social (SAS) considered...

10.1136/jnnp.72.6.701 article EN Journal of Neurology Neurosurgery & Psychiatry 2002-06-01

To prospectively evaluate the impact of subthalamic nucleus (STN) stimulation on social adjustment in patients with Parkinson disease (PD).Before and 18 to 24 months after bilateral STN stimulation, authors assessed 29 PD for motor disability, cognition (Mattis dementia rating scale, frontal score), psychiatric morbidity (Mini-5.0.0, MADRS, BAS), quality life (PDQ-39), (Social Adjustment Scale), psychological status using unstructured in-depth interviews.Despite marked improvement...

10.1212/01.wnl.0000234880.51322.16 article EN Neurology 2006-06-26

Collective evidence has strongly suggested that deep brain stimulation (DBS) is a promising therapy for Tourette syndrome.To assess the efficacy and safety of DBS in multinational cohort patients with syndrome.The prospective International Deep Brain Stimulation Database Registry included 185 medically refractory syndrome who underwent implantation from January 1, 2012, to December 31, 2016, at 31 institutions 10 countries worldwide.Patients symptoms received centromedian thalamic region (93...

10.1001/jamaneurol.2017.4317 article EN JAMA Neurology 2018-01-16

Numerous factors need to be taken into account in deciding whether a patient with Parkinson's disease (PD) is candidate for deep brain stimulation. Patient-related personal including age and the presence of other comorbid disorders considered. Neuropsychological neuropsychiatric concerns relate both presurgical status potential surgery result new problems postoperatively. A number related underlying PD considered, specific parkinsonian motor indications (e.g., tremor, bradykinesia, gait...

10.1002/mds.20955 article EN Movement Disorders 2006-01-01

Stimulation of the subthalamic nucleus is an effective treatment for advanced Parkinson disease (PD) and currently performed after a mean duration 14 years, when severe motor complications have resulted in marked loss quality life. We examined whether surgery at early stage would maintain life as well improve function.Twenty patients with PD short (time elapsed since first symptom +/- SD: 6.8 1.0 years) mild to moderate signs (Unified Parkinson's Disease Rating Scale III "off" medication: 29...

10.1212/01.wnl.0000250253.03919.fb article EN Neurology 2006-12-07

Abstract The “Ardouin Scale of Behavior in Parkinson's Disease” is a new instrument specifically designed for assessing mood and behavior with view to quantifying changes related disease, dopaminergic medication, non‐motor fluctuations. This study was aimed at analyzing the psychometric attributes this scale patients disease without dementia. In addition scale, following measures were applied: Unified Disease Rating Scale, Montgomery Asberg Depression Lille Apathy Bech Rafaelsen Mania...

10.1002/mds.26223 article EN Movement Disorders 2015-03-21

Background Repetitive behaviours (RB) in patients with Gilles de la Tourette syndrome (GTS) are frequent. However, a controversy persists whether they manifestations of obssessive-compulsive disorder (OCD) or correspond to complex tics. Methods 166 consecutive GTS aged 15–68 years were recruited and submitted extensive neurological, psychiatric psychological evaluations. RB evaluated by the YBOCS symptom checklist Mini International Neuropsychiatric Interview (M.I.N.I), classified on basis...

10.1371/journal.pone.0012959 article EN cc-by PLoS ONE 2010-09-24

<b>Objective: </b> To assess the effects of bilateral pallidal deep brain stimulation (DBS) on mood and cognitive performance in patients with dystonia before surgery (at baseline, while received their usual treatment) 12 months postoperatively (while neurostimulation medications) a multicenter prospective study. <b>Methods: Twenty-two primary generalized were evaluated tests focused executive functions. The authors considered patients9 severe disability selected following tests: Raven...

10.1212/01.wnl.0000216131.41563.24 article EN Neurology 2006-05-01

Tourette Syndrome (TS) is a neuropsychiatric disease characterized by combination of motor and vocal tics. Deep brain stimulation (DBS), already widely utilized for Parkinson's other movement disorders, an emerging therapy select severe cases TS that are resistant to medication behavioral therapy. Over the last two decades, DBS has been used experimentally manage cases. The results case reports small series have variable but in general positive. reported interventions have, however,...

10.3389/fnins.2016.00170 article EN cc-by Frontiers in Neuroscience 2016-04-24

After more than 50 years of treating Parkinson's disease with l-DOPA, there are still no guidelines on setting the optimal dose for a given patient. The dopamine transporter type 1, now known as solute carrier family 6 (neurotransmitter transporter), member 3 (SLC6A3) is most powerful determinant neurotransmission and might therefore influence treatment response. We recently demonstrated that methylphenidate (a inhibitor) effective in patients motor gait disorders. objective present study...

10.1093/brain/awv063 article EN Brain 2015-03-23

Bilateral high-frequency continuous stimulation of the internal globus pallidus or subthalamic nucleus constitutes a new therapeutic approach for treatment patients with severe PD. The authors report two in whom failed to give long-term relief and was successfully replaced by bilateral stimulation. results emphasize reversibility deep brain therapy suggest that target is preferable pallidal target.

10.1212/wnl.55.5.728 article EN Neurology 2000-09-12
Margherita Fabbri Vanessa Rousseau Jean‐Christophe Corvol Agnès Sommet Florence Tubach and 95 more Yann De Rycke Nathalie Bertille Yajiththa Selvarasa Stéphanie Carvalho Véronique Chaigneau Christine Brefel‐Courbon Fabienne Ory‐Magne Samuel Tessier Mélissa Tir Matthieu Béreau Wassilios G. Meissner Claire Thiriez Ana Marqués Philippe Rémy Vincent Schneider Elena Moro Luc Defebvre Jean Luc Houeto Stéphane Prange Alexandre Eusébio Christian Gény Solène Frismand Philippe Damier Caroline Giordana Reuther Giovanni Castelnovo Isabelle Bénatru Anne Doé de Maindreville Sophie Drapier David Maltête Ouhaïd Lagha‐Boukbiza Olivier Rascol Mickael Aubignat Éloi Magnin Pr Pierre Burbaud Pr Dominique Guehl Alexandra Foubert‐Samier Brice Laurens Thomas Boraud Sylvain Vergnet David Bendetowicz Thomas Palpacuer Bérengère Debilly Philippe Derost Charlotte Beal Hayet Salhi Alice Dormeuil Aimée Petit Alban Gravier Gwendoline Dupont Lucie Garnier Valérie Fraix Anna Castrioto Sara Meoni Nicolas Carrière Téodor Danaila Chloé Laurencin Stéphane Thobois Jean‐Philippe Azulay Frédérique Fluchère Mahmoud Charif Marie‐Christine Picot Lucie Hopes Anne-Gaëlle Corbillé Tiphaine Rouaud Pascal Derkinderen Cosmin Alecu Charlotte Héraud Marie De Verdal Bertrand Degos Graziella Mangone Sara Sambin Aymeric Lanore Thomas Courtin Louise‐Laure Mariani David Bendetowicz Fouad Khoury Poornima Jayadev Menon Florence Cormier‐Dequaire Emmanuel Flamand‐Roze David Grabli Élodie Hainque Marie Vidhaillet Aurélie Méneret Cécile Delorme Cendrine Foucard Florian von Raison Alexis Elbaz Andreas Hartmann Vincent Leclercq Solène Ansquer Frédérique Leh Marion Leclercq Guillaume Costentin Lagha Boukbiza Christine Brefel Courbon

10.1007/s00702-024-02772-4 article EN Journal of Neural Transmission 2024-04-05

Freezing of gait (FoG) is a debilitating symptom Parkinson's disease (PD) with limited response to dopaminergic medication and subthalamic deep brain stimulation (STN-DBS). Substantia nigra pars reticulata (SNr) could improve FoG. To analyze the effect combined STN-SNr at different frequencies on We performed double-blind, cross-over, randomized pilot trial involving STN-DBS treated PD patients Participants received: high-frequency (HF) (S), HF-STN SNr (C1), low-frequency (LF) (C2), for one...

10.1177/1877718x241292315 article EN cc-by-nc Journal of Parkinson s Disease 2025-01-17

The fiber-dissection technique provides unique 3-dimensional anatomic knowledge of the white matter.To better identify frontostriatal pathways in human brain, we used a to reconstruct neural connections between frontal cortex and nucleus accumbens (NAcc), which is most ventral extent striatum.Thirty previously frozen, formalin-fixed brains were dissected under operating microscope using modified technique, primarily reported by Klingler.Our serial dissections 30 brain specimens clearly...

10.1227/neu.0b013e3182098e48 article EN Neurosurgery 2011-01-18

Background: Mood symptoms negatively affect quality of life Parkinson's disease (PD); however little is known about the impact behavioral disorders such as impulse control disorders, and non-motor fluctuations on life. Objective: To assess mood disorder s in PD. Methods: 136 (84% male) PD were included (mean age: 61±8y; mean duration disease: 8.8±5.4y). symptoms, detected quantified using recently validated "Ardouin Scale Behavior Disease". Motor assessed UPDRS with "39-item Disease...

10.3233/jpd-150747 article EN Journal of Parkinson s Disease 2016-03-30

Background This phase 2 randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of nicotinic acetylcholine receptor α7 agonist AQW051 in patients with Parkinson's disease levodopa-induced dyskinesia. Methods Patients idiopathic moderate to severe dyskinesia were randomized 10 mg (n = 24), 50 or placebo 23) once daily for 28 days. Coprimary end points change Modified Abnormal Involuntary Movement Scale Unified Disease Rating part III scores. Secondary outcomes...

10.1002/mds.26569 article EN Movement Disorders 2016-03-15
Christina Fevga Christelle Tesson Ana Carreras Mascaro Thomas Courtin Riaan van Coller and 95 more Salma Sakka Federico Ferraro Nouha Farhat Soraya Bardien Mariem Damak Jonathan Carr Mélanie Ferrien Valerie Boumeester Jasmijn Hundscheid Nicola Grillenzoni Irini A. Kessissoglou Demy J.S. Kuipers Marialuisa Quadri Y. Agid Mathieu Anheim Michel Borg Alexis Brice Emmanuel Broussolle Jean‐Christophe Corvol Philippe Damier Luc Defebvre Alexandra Dürr Franck Durif Jean Luc Houeto Paul Krack Stephan Klebe Suzanne Lesage Ebba Lohmann María Martínez Graziella Mangone Louise‐Laure Mariani Pierre Pollak Olivier Rascol François Tison Christine Tranchant Marc Vérin François Viallet Marie Vidailhet Ebba Lohmann Murat Emre Haşmet Hanağası Başar Bılgıç Bingxin Lu Mustapha Benmahdjoub Mohammed Arezki Sofiane Bouchetara Traki Benhassine Mériem Tazir Mouna Ben Djebara Riadh Gouider Sawssan Ben Romdhan Chokri Mhiri Ahmed Bouhouche Vincenzo Bonifati Wim Mandemakers Anneke J.A. Kievit Agnita J.W. Boon Joaquim J. Ferreira Leonor Correia Guedes Murat Emre Haşmet Hanağası Başar Bılgıç Zeynep Tüfekçıoğlu Bülent Elibol Okan Dog.u Murat Gültekin Hsin Fen Chien Egberto Reis Barbosa Laura Bannach Jardim Carlos Roberto de Mello Rieder Hsiu‐Chen Chang Chin‐Song Lu Yah-Huei Wu-Chou Tu‐Hsueh Yeh Leonardo Lopiano Cristina Tassorelli C. Pacchetti Cristoforo Comi Francesco Raudino Laura Bertolasi Michèle Tinazzi A. Bonizzato C Ferracci Roberto Marconi Marco Guidi Marco Onofrj Astrid Thomas Nicola Vanacore G. Meco Edito Fabrizio Giovanni Fabbrini Alfredo Berardelli Fabrizio Stocchi Laura Vacca Paolo Barone

Abstract The protein phosphatase 2A complex (PP2A), the major Ser/Thr in brain, is involved a number of signalling pathways and functions, including regulation crucial proteins for neurodegeneration, such as alpha-synuclein, tau LRRK2. Here, we report identification variants PTPA/PPP2R4 gene, encoding PP2A activator, two families with early-onset parkinsonism intellectual disability. We carried out clinical studies genetic analyses, genome-wide linkage analysis, whole-exome sequencing,...

10.1093/brain/awac326 article EN cc-by-nc Brain 2022-09-08

Abstract Subthalamic nucleus (STN) stimulation improves motor disability and quality of life in patients with advanced Parkinson's disease (PD). Short‐term mortality is low, but little known about long‐term mortality. We assessed causes death 171 consecutive PD treated by STN stimulation. Surgery was performed after a median lagtime 13 years from onset at age 57 years. The follow‐up surgery 41 months. Sixteen died 8 to 83 months neurosurgery. Poorer cognitive function the only predictive...

10.1002/mds.21264 article EN Movement Disorders 2006-12-05

Abstract Background Several studies have shown the influence of perceptions aging on cognitive functioning and mental physical health older people. These relationships not to date been studied in France where validated instruments are lacking. The primary objective this study was validate a French-language version Aging Perceptions Questionnaire (APQ) French general population aged 65 over. secondary stability dimensions instrument among participants 55 64. Methods proposed cohort...

10.1186/1471-2318-12-17 article EN cc-by BMC Geriatrics 2012-04-30

Pain is a frequent and disabling non-motor symptom of Parkinson's Disease (PD). Yet, no treatment to date can efficiently reduce this pain. This article investigates the brain functional connectivity PD patients with central pain effects levodopa oxycodone on connectivity. Thirty-eight received either levodopa, oxycodone, or placebo during an eight-week period. intensity was evaluated using Visual Analogue Scale resting-state measured before after treatments. were also separated into two...

10.1016/j.ynirp.2024.100197 article EN cc-by-nc-nd Neuroimage Reports 2024-02-02

Abstract Non-motor aspects in dystonia are now well recognized. The sense of agency, which refers to the experience controlling one's own actions, has been scarcely studied dystonia, even though its disturbances can contribute movement disorders. Among various brain structures, cerebral cortex, cerebellum, and basal ganglia involved shaping agency. In myoclonus resulting from a dysfunction motor network, an altered agency may clinical phenotype condition. this study, we compared explicit...

10.1093/braincomms/fcae105 article EN cc-by Brain Communications 2024-01-01

Several postmortem studies have shown iron accumulation in the substantia nigra of Parkinson's disease patients. Iron concentration can be estimated via MRI-R2∗ mapping. To assess changes R2∗ occurring patients compared to controls, a multicentre transversal study was carried out on large cohort (n = 163) with matched controls 82). In this study, 44 and 11 were removed due motion artefacts, 21 patient 6 preserve matching. Thus, 98 65 age sex-matched healthy subjects selected enough image...

10.1016/j.nicl.2022.103231 article EN cc-by-nc-nd NeuroImage Clinical 2022-01-01
Coming Soon ...